- Home
- CEE vs FBIO Comparison
CEE vs FBIO Comparison
Compare CEE & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEE
- FBIO
- Stock Information
- Founded
- CEE 1990
- FBIO 2006
- Country
- CEE Germany
- FBIO United States
- Employees
- CEE N/A
- FBIO N/A
- Industry
- CEE Finance Companies
- FBIO Biotechnology: Pharmaceutical Preparations
- Sector
- CEE Finance
- FBIO Health Care
- Exchange
- CEE Nasdaq
- FBIO Nasdaq
- Market Cap
- CEE 105.5M
- FBIO 88.7M
- IPO Year
- CEE N/A
- FBIO N/A
- Fundamental
- Price
- CEE $15.86
- FBIO $2.52
- Analyst Decision
- CEE
- FBIO Strong Buy
- Analyst Count
- CEE 0
- FBIO 2
- Target Price
- CEE N/A
- FBIO $16.50
- AVG Volume (30 Days)
- CEE 22.0K
- FBIO 1.0M
- Earning Date
- CEE 01-01-0001
- FBIO 11-13-2025
- Dividend Yield
- CEE 3.86%
- FBIO N/A
- EPS Growth
- CEE N/A
- FBIO N/A
- EPS
- CEE N/A
- FBIO N/A
- Revenue
- CEE N/A
- FBIO $59,301,000.00
- Revenue This Year
- CEE N/A
- FBIO $31.85
- Revenue Next Year
- CEE N/A
- FBIO $44.43
- P/E Ratio
- CEE N/A
- FBIO N/A
- Revenue Growth
- CEE N/A
- FBIO N/A
- 52 Week Low
- CEE $7.80
- FBIO $1.33
- 52 Week High
- CEE $10.32
- FBIO $4.20
- Technical
- Relative Strength Index (RSI)
- CEE 54.09
- FBIO 38.92
- Support Level
- CEE $15.41
- FBIO $2.47
- Resistance Level
- CEE $16.07
- FBIO $2.61
- Average True Range (ATR)
- CEE 0.43
- FBIO 0.14
- MACD
- CEE 0.07
- FBIO -0.04
- Stochastic Oscillator
- CEE 80.15
- FBIO 20.93
About CEE The Central and Eastern Europe Fund Inc. (The)
CENTRAL & EASTERN EUROPE FUND, INC. is a closed-end management investment company. The Fund's objective is to seek long-term capital appreciation. It invests in the equity or equity-linked securities of issuers domiciled in Central and Eastern Europe.
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.